Europe biodefense market set to reach $6.3 billion by 2028
The Europe biodefense market size is projected to reach a valuation $6.3 billion by 2028, according to a recent study from market research firm Graphical Research.
The rising prevalence of infectious diseases is driving Europe biodefense market growth. Since the World Health Organization (WHO) labeled the COVID-19 outbreak a pandemic in March 2020, the virus has caused more than 2.5 million deaths worldwide, as per news-medical.net.
Not just that, over the last two decades, several diseases such as swine flu, bird flu, and other viral diseases have become localized pandemics. Even seasonal flus have become more severe during the previous two decades. As a result, bio attenuation is necessary not just for COVID-19 protection, but also for general viral protection over the next five to 10 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze